Anticryptococcal activity of Voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: Comparison with Fluconazole and effect of human serum

Mycopathologia

Volumn 142, Issue 1, 1998, Pages 3-7

  Brummer, Elmer ^a,b   Kamei, Katsuhiko ^a   Miyaji, Mokoto ^a  

^a CHIBA UNIVERSITY   (Japan)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

C. neoformans var. gattii; C. neoformans var. neoformans; Fluconazole; Serum; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ARTICLE; BACTERIAL COUNT; COMPARATIVE STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; HUMAN; MICROBIOLOGICAL EXAMINATION;

ANTIFUNGAL AGENTS; COLONY COUNT, MICROBIAL; CRYPTOCOCCUS NEOFORMANS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

BACTERIA (MICROORGANISMS); CRYPTOCOCCUS BACILLISPORUS; CRYPTOCOCCUS NEOFORMANS VAR. NEOFORMANS; FILOBASIDIELLA NEOFORMANS;

EID: 0031728845     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006999727607     Document Type: Article

References (11)

1. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole for cryptococcal meningitis and cryptococcosis. Arch Internal Med 1989; 149: 2302-2308.
2. Eng RH, Bishburg Ed Smith EM. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med 1986; 81: 19-23.
3. Lopez-Martinez R, Soto-Hernandez JL, Ostrosky-Zeichner L, Castanon-Olivares LR, Angles-Morales V, Sotelo J. Cryptococcus neoformans var gattii among patients with cryptococcal meningitis in Mexico. First observations. Mycopathologia 1996; 134: 61-64.
4. Sukroongreung S, Nilaku C, Ruangsomboon O, Chuakul W, Eampokalap B. Serotypes of Cryptococcus neoformans isolated from patients prior to and during the AIDS era in Thailand. Mycopathologia 1996; 135: 75-78.
5. Mitchell DH, Sorrell TC, Allworth AM, Heath CH, McGregor AR, Papanaoum K, Richards MJ, Gottlieb T. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestation and outcome. Clin Infect Dis 1995; 20: 611-616.
6. Powderly WG, Saag MS, Cloud GA, Robinson P, Jacobson JM, Graybill JR, Sugar AM, McAuliffe VJ, Follansbee SE, Tuazon CV, Stern JJ, Feinberg J, Hafner R, Dismukes WE. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome. N Eng J Med 1992; 326: 793-798.
7. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (Voriconazole) in a patient with acute leukaemia. Brit J Haematol 1997; 97: 663-665.
8. Fromtling RA, Castaner J. Voriconazole (UK-109496). Drugs of the Future 1996; 21(3): 266-271.
9. Grover DD, Brummer E, Stevens DA. Study of the role of iron in the anitcryptococcal activity of human serum and fluconazole. Mycopathologia 1996; 133: 71-77.
10. Nassar F, Brummer E, Stevens DA. Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity. Antimicrob Agents Chemother 1995; 39: 2490-2493.
11. Clancy CJ, Yu CY, Nguyen MH. In vitro activity of voriconazole against yeasts and comparison with fluconazole. Abstr. E-88. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997, American Society for Microbiology. Washington, D.C.